Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04270409
Recruitment Status : Recruiting
First Posted : February 17, 2020
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objectives:

  • Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM)
  • Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to lenalidomide and dexamethasone in subjects with high-risk SMM

Secondary Objectives:

Safety run-in

  • To assess overall response rate (ORR)
  • To assess duration of response (DOR)
  • To assess minimal residual disease (MRD) negativity in participants achieving very good partial response (VGPR) or complete response (CR)
  • To assess time to diagnostic (SLiM CRAB) progression or death
  • To assess time to first-line treatment for multiple myeloma (MM)
  • To assess the potential immunogenicity of isatuximab
  • Impact of abnormal cytogenetic subtype

Randomized Phase 3 - Key Secondary Objectives:

To compare between the arms

  • MRD negativity
  • Sustained MRD negativity
  • Second progression-free survival (PFS2)
  • Overall survival

Other Secondary Objectives:

To evaluate in both arms

  • CR rate
  • ORR
  • DOR
  • Time to diagnostic (SLiM CRAB) progression
  • Time to first-line treatment for MM
  • Safety and tolerability
  • Pharmacokinetics (PK)
  • Potential of isatuximab immunogenicity
  • Clinical outcome assessments (COAs)

Condition or disease Intervention/treatment Phase
Plasma Cell Myeloma Drug: Isatuximab SAR650984 Drug: Lenalidomide Drug: Dexamethasone Phase 3

Detailed Description:
Study duration is expected to be approximately 10 years, including a 28-day screening period, followed by an up to 36-month treatment period, and a follow-up period of approximately 7 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With High-risk Smoldering Multiple Myeloma
Actual Study Start Date : June 16, 2020
Estimated Primary Completion Date : January 2028
Estimated Study Completion Date : May 2033


Arm Intervention/treatment
Experimental: Isatuximab, lenalidomide, and dexamethasone (ILd)
Isatuximab intravenous (IV) administration on Days 1, 8, 15, and 22 during Cycle 1 (28 days per cycle), and Days 1 and 15 during Cycles 2-12, and Day 1 during subsequent cycles; lenalidomide per os (PO) administration on Days 1 to 21; and dexamethasone IV administration only on Day 1 during Cycle 1 and PO on Days 8, 15 and 22 of Cycle 1 and Days 1, 8, 15, and 22 of subsequent cycles
Drug: Isatuximab SAR650984
Pharmaceutical for: Solution for infusion Route of administration: Intravenous
Other Name: Sarclisa

Drug: Lenalidomide
Pharmaceutical form: Capsules Route of administration: Oral

Drug: Dexamethasone
Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous

Active Comparator: Lenalidomide and dexamethasone (Ld)
Lenalidomide PO administration on Days 1 to 21 and dexamethasone PO administration on Days 1, 8, 15, and 22 of every 28-day cycle
Drug: Lenalidomide
Pharmaceutical form: Capsules Route of administration: Oral

Drug: Dexamethasone
Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous




Primary Outcome Measures :
  1. Safety assessment: adverse events (AEs) [ Time Frame: Baseline to 30 days after last study treatment administration (up to approximately 100 months after first study treatment) ]
    Number of participants with AEs

  2. Plasma concentration of isatuximab: Cmax [ Time Frame: Up to approximately 24 months ]
    Maximum concentration observed after the first infusion (Cmax)

  3. Receptor density/receptor occupancy (safety run-in) [ Time Frame: Baseline to Cycle 2 Day 1 (each cycle is 28 days) ]
    Change in CD38 receptor occupancy from baseline

  4. Progression-free survival (PFS) randomized Phase 3 [ Time Frame: Up to approximately 85 months ]
    Time from randomization to MM (SLiM CRAB criteria) or other related conditions based on independent review committee assessment according to 2014 International Myeloma Working Group (IMWG) criteria or death from any cause, whichever happens first


Secondary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: Up to approximately 85 months ]
    Proportion of participants with best overall response recorded as partial response or better according to 2016 IMWG criteria

  2. Duration of response (DOR) [ Time Frame: Up to approximately 85 months ]
    Time from the date of the first response to date of progressive disease or death, whichever happens first

  3. Minimal residual disease (MRD) negativity [ Time Frame: Up to approximately 85 months ]
    Number of participants for whom MRD is negative

  4. Time to diagnostic (SLiM CRAB) progression or death [ Time Frame: Up to approximately 85 months ]
    Time from randomization to diagnosis of SLiM-CRAB or other related conditions, progression, or death from any cause

  5. Time to first-line treatment for multiple myeloma (MM) [ Time Frame: Up to approximately 85 months ]
    Time from randomization to first-line treatment for MM

  6. Immunogenicity: Incidence of anti-drug antibodies (ADA) [ Time Frame: Up to approximately 24 months ]
    Number of participants with anti-drug antibodies against isatuximab

  7. Sustained MRD negativity [ Time Frame: Up to approximately 85 months ]
    Number of participants with sustained MRD negativity (sample is still negative at least 1 year after the first negativity assessment)

  8. Second PFS (PFS2) [ Time Frame: Up to approximately 120 months ]
    Time from randomization to date of second objective progressive disease or death from any cause

  9. Overall survival [ Time Frame: Up to approximately 144 months ]
    Time from date of randomization to death from any cause

  10. Complete response rate [ Time Frame: Up to approximately 85 months ]
    Percentage of particpants with a CR as defined by 2016 IMWG response criteria

  11. Safety assessment: adverse events (AEs) [ Time Frame: Baseline to 30 days after last study treatment administration (up to approximately 100 months after first study treatment) ]
    Number of participants with AEs

  12. Plasma concentration of isatuximab [ Time Frame: Up to approximately 24 months ]
    Maximum concentration observed after the first infusion (Cmax)

  13. European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 [ Time Frame: Baseline to follow-up (up to approximately 10 years) ]
    Mean change from baseline scores will be assessed, with responses ranging from 1=not at all to 4=very much or 1=very poor to 7=excellent; higher scores represent a better level of physical functioning

  14. EORTC QLQ-MY20 [ Time Frame: Baseline to follow-up (up to approximately 10 years) ]
    Mean change from baseline in scores will be assessed using a 4-point scale, with responses ranging from 1=not at all to 4=very much; higher scores represent better perspectives of the future and higher level of symptomatology

  15. EQ-5D-5L [ Time Frame: Baseline to follow-up (up to approximately 10 years) ]
    Mean change from baseline scores will be assessed from 5 items, with responses ranging from 'no' to 'extreme problems'; health state utility values (HSUVs) are generated by multiplying the item scores by country specific value sets; health status is assessed via a VAS; higher scores = higher HSUV/health status

  16. Economic questionnaire [ Time Frame: Baseline to follow-up (up to approximately 10 years) ]
    Mean change from baseline scores will assess work productivity, resource utilization and working days missed by a caregiver; higher scores represent greater impact on work/productivity and resources

  17. Patient's Qualitative Assessment of Treatment Version 2 (PQAT-v2) [ Time Frame: End of treatment (up to approximately 10 years) ]
    Patient's qualitative assessment of treatment will be assessed using a 10 point visual analogue/numeric rating scale with response anchors of 'not beneficial at all' to 'extremely beneficial'; higher scores represent greater patient-perceived benefits of treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Participants who are diagnosed within 5 years with SMM (per International Myeloma Working Group [IMWG] criteria), defined as serum M-protein ≥30 g/L or urinary M-protein ≥500 mg per 24 hour or both, and/or clonal bone marrow plasma cells (BMPCs) 10% to <60%, and absence of myeloma defining events or other related conditions and with high-risk SMM
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 or 2
  • Capable of giving voluntary written informed consent

Exclusion criteria:

  • Evidence of any of the following calcium, renal failure, anemia, bone lesions (CRAB) criteria or Myeloma Defining Events (SLiM CRAB) detailed below (attributable to the participants SMM involvement):

    • Increased calcium levels: Corrected serum calcium >1 mg/dL above the ULN or >11 mg/dL
    • Renal insufficiency: Determined by glomerular filtration rate (GFR) <40 mL/min/1.73 m² (Modification of Diet in Renal Disease [MDRD] Formula) or serum creatinine >2 mg/dL
    • Anemia (hemoglobin 2 g/dL below lower limit of normal or <10 g/dL or both) transfusion support or concurrent treatment with erythropoietin stimulating agents is not permitted
    • ≥ 1 bone lytic lesion
    • BMPCs ≥60%
    • Serum involved/uninvolved FLC ratio ≥100
    • Whole body magnetic resonance imaging (WB-MRI) or positron emission tomography-computed tomography (PET-CT) with more than 1 focal lesion (≥5 mm in diameter by MRI)
  • Primary systemic amyloid light-chain (immunoglobulin light chain) amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), standard risk smoldering myeloma, soft tissue plasmacytoma, symptomatic myeloma
  • Uncontrolled infection within 28 days prior to randomization in Phase 3 or first study intervention administration in safety run-in
  • Clinically significant cardiac disease, including:

    • Myocardial infarction within 6 months with left ventricular dysfunction or uncontrolled ischemic cardiac disease before Cycle 1 Day 1, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association Class III-IV)
    • Uncontrolled cardiac arrhythmia (Grade 2 or higher by NCI-CTCAE Version 5.0) or clinically significant electrocardiogram (ECG) abnormalities
  • Known acquired immunodeficiency syndrome (AIDS)-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A (defined as positive hepatitis A antigen or positive IgM). HIV serology at screening will be tested for German participants and any other country where required as per local regulations and serology hepatitis B and C at screening will be tested for all participants

    • Uncontrolled or active HBV infection: Patients with positive HBsAg and/or HBV DNA

Of note:

Patient can be eligible if anti-HBc IgG positive (with or without positive anti-HBs) but HBsAg and HBV DNA are negative. If anti-HBV therapy in relation with prior infection was started before initiation of IMP, the anti-HBV therapy and monitoring should continue throughout the study treatment period.

Patients with negative HBsAg and positive HBV DNA observed during screening period will be evaluated by a specialist for start of anti-viral treatment: study treatment could be proposed if HBV DNA becomes negative and all the other study criteria are still met.

Active HCV infection: positive HCV RNA and negative anti-HCV

Of note:

Patients with antiviral therapy for HCV started before initiation of IMP and positive HCV antibodies are eligible. The antiviral therapy for HCV should continue throughout the treatment period until seroconversion.

Patients with positive anti-HCV and undetectable HCV RNA without antiviral therapy for HCV are eligible

  • Malabsorption syndrome or any condition that can significantly impact the absorption of lenalidomide
  • Any of the following within 3 months prior to randomization (or first study intervention administration in safety run-in cohort): treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event
  • Received treatment (eg surgery, radiotherapy, medication) for a malignancy within 3 years of randomization (or first study intervention administration in safety run-in cohort)
  • Prior exposure to approved or investigational treatments for SMM or MM (including but not limited to conventional chemotherapies, immunomodulatory imid drugs, or Proteasome inhibitors); concurrent use of bisphosphonates or receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor denosumab is not permitted; however, prior bisphosphonates or once-a-year intravenous bisphosphonate given for the treatment of osteoporosis is permitted
  • Ongoing treatment with corticosteroids with a dose >10 mg prednisone or equivalent per day at the time of randomization (or first study intervention administration in safety run-in cohort)
  • Women of childbearing potential or male participant with women of childbearing potential who do not agree to use a highly effective method of birth control
  • Vaccination with a live vaccine 4 weeks before the start of the study drug. Seasonal flu vaccines that do not contain live virus are permitted

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04270409


Contacts
Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext option 6 Contact-US@sanofi.com

Locations
Layout table for location information
Australia
Investigational Site Number 0360002 Recruiting
Fitzroy, Australia, 3065
Investigational Site Number 0360007 Recruiting
Heidelberg West, Australia, 3081
Investigational Site Number 0360006 Recruiting
Nedlands, Australia, 6009
Investigational Site Number 0360004 Recruiting
Richmond, Australia, 3121
Investigational Site Number 0360001 Recruiting
Wollongong, Australia, 2500
Denmark
Investigational Site Number 2080002 Recruiting
Roskilde, Denmark, 4000
France
Investigational Site Number 2500007 Recruiting
Grenoble Cedex 9, France, 38043
Investigational Site Number 2500006 Recruiting
La Roche Sur Yon Cedex 9, France, 85925
Investigational Site Number 2500009 Recruiting
Metz Cedex 03, France, 57085
Korea, Republic of
Investigational Site Number 4100001 Recruiting
Seoul, Korea, Republic of, 03722
Investigational Site Number 4100003 Active, not recruiting
Seoul, Korea, Republic of
Lithuania
Investigational Site Number 4400001 Recruiting
Vilnius, Lithuania, 08661
Norway
Investigational Site Number 5780001 Recruiting
Oslo, Norway, 0450
Spain
Investigational Site Number 7240004 Recruiting
Barcelona, Spain, 08036
Investigational Site Number 7240006 Recruiting
Pamplona, Spain, 31008
Investigational Site Number 7240007 Recruiting
Salamanca, Spain, 37007
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT04270409    
Other Study ID Numbers: EFC15992
2019-003139-47
U1111-1222-7068 ( Other Identifier: UTN )
First Posted: February 17, 2020    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Sanofi:
Anti-CD38 monoclonal antibody
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Smoldering Multiple Myeloma
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Precancerous Conditions
Hypergammaglobulinemia
Dexamethasone
Lenalidomide
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents